Abstract:Cancer is a significant health hazard of the 21st century, and GLOBOCAN predicts increasing cancer incidence in the coming decades. Though several conventional treatment modalities exist, most of them end up causing off-target and debilitating effects, and drug resistance acquisition. Advances in our understanding of tumor molecular biology offer alternative strategies for precise, robust, and potentially less toxic treatment paradigms for circumventing the disease at the cellular and molecular level. Several deregulated molecules associated with tumorigenesis have been developed as targets in RNA interference (RNAi) based cancer therapeutics. RNAi, a post-transcriptional gene regulation mechanism, has significantly gained attention because of its precise multi-targeted gene silencing. Although the RNAi approach is favorable, the direct administration of small oligonucleotides has not been fruitful because of their inherent lower half-lives and instability in the biological systems. Moreover, the lack of an appropriate delivery system to the primary site of the tumor that helps determine the potency of the drug and its reach, has limited the effective medical utilization of these bio-drugs. Nanotechnology, with its unique characteristics of enhanced permeation and better tumor-targeting efficiency, offers promising solutions owing to the various possibilities and amenability for modifications of the nanoparticles to augment cancer therapeutics. Nanoparticles could be made multimodal, by designing and synthesizing multiple desired functionalities, often resulting in unique and potentially applicable biological structures. A small number of Phase I clinical trials with systemically administered siRNA molecules conjugated with nanoparticles have been completed and the results are promising, indicating that, these new combinatorial therapies can successfully and safely be used to inhibit target genes in cancer patients to alleviate some of the disease burden. In this review, we highlight different types of nano-based delivery strategies for engineering Nano-RNAi-based bio drugs. Furthermore, we have highlighted the insights gained from current research that are entering the preclinical evaluation and information about initial clinical developments, shaping the future for next generation cancer therapeutics.

siRNA-based therapy for gastric adenocarcinoma: what's next step?

siRNA-based strategies to combat drug resistance in gastric cancer

siRNA delivery systems for cancer treatment

Oral delivery of RNAi for cancer therapy

RNAi treatment has been shown to successfully modify human-related target gene expression, including cancer. It has the capacity to control non-standard oncogenes, such as oncogenic lncRNAs

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise

Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying Both Ligand and Sirna

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Smart Physicochemical-triggered Chitosan-based Nanogels for siRNA Delivery and Gene Therapy: A Focus on Emerging Strategies and Paradigms for Cancer Therapy

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Small interfering RNA for experimental cancer therapy.

RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics

Efficient nanocarriers of siRNA therapeutics for cancer treatment

Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now?

A novel strategy for cancer gene therapy: RNAi

A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells

Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?

Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics

Precise Targeting Therapy of Orthotopic Gastric Carcinoma by siRNA and Chemotherapeutic Drug Codelivered in pH‐Sensitive Nano Platform